

CORRECTION

Open Access



Correction: Evaluation and testing of polymethylmetacrylic (PMMA) bone cements with admixed Amphotericin B

Florian A. Frank^{1,2*}, Barbara Krampitz³, Julia Steiner⁴, Rainer Strathausen³, Mario Morgenstern^{1,2}, Martin Clauss^{1,2} and Klaus-Dieter Kühn⁴

Correction: Journal of Orthopaedic Surgery and Research (2025) 20:151

<https://doi.org/10.1186/s13018-025-05565-x>

In Table 1 of this article, the powder data '30 g/0.8 g, 30 g/0.8 g, 100 g/2.66 g, 50 g/1.33 g' under the heading 'AmBisome[®] (powder/pure drug)' were mistakenly listed in 'g' instead of 'mg'. The corresponding data should read as '30 mg/0.8 g, 30 mg/0.8 g, 100 mg/2.66 g, 50 mg/1.33 g'.

The column headings 'Amphotericin B (pure drug)' has been changed to

'Added pure Amphotericin B powder (active ingredient)' and

'AmBisome[®] (powder/pure drug)' has been changed to 'Added AmBisome[®] (1,33 g contains 50 mg pure amphotericin B powder (active ingredient/total amount of powder))'.

Both the incorrect and the corrected Table 1 are displayed below.

The original article can be found online at <https://doi.org/10.1186/s13018-025-05565-x>.

*Correspondence:

Florian A. Frank
florian.frank@t-online.de

¹ Centre for Musculoskeletal Infections (ZMSI), University Hospital of Basel, 4031 Basel, Switzerland

² Department of Orthopaedics and Traumatology, University Hospital of Basel, 4031 Basel, Switzerland

³ Heraeus Medical, Philipp-Reis-Strasse 8-13, 61273 Wehrheim, Germany

⁴ Department of Orthopaedics and Traumatology, Medical University of Graz, 8036 Graz, Austria



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

Incorrect Table 1

Table 1 Formulations of PMMA cement with amphotericin B tested

Cement	Amphotericin B (pure drug)	AmBisome® (powder/pure drug)
Palacos R	0.5 g	
	0.8 g	30 g/0.8 g
Palacos R + G	0.8 g	30 g/0.8 g
	2.66 g	100 g/2.66 g
Copal G + C	1.33 g	50 g/1.33 g

Corrected Table 1

Table 1 Formulations of PMMA cement with amphotericin B tested

Cement	Added pure amphotericin B powder (active ingredient)	Added AmBisome® (1,33 g contains 50 mg pure amphotericin B powder (active ingredient/total amount of powder))
Palacos R	0.5 g	
	0.8 g	30 mg/0.8 g
Palacos R + G	0.8 g	30 mg/0.8 g
	2.66 g	100 mg/2.66 g
Copal G + C	1.33 g	50 mg/1.33 g

In Table 2, the data ‘Palacos R + 30 g AmBisome®’, Palacos R + G + 30 g AmBisome®, Palacos R + G + 100 g AmBisome® and Copal G + C + 50 g AmBisome® under the heading ‘Cement formulation’ were mistakenly listed in ‘g’ instead of ‘mg’. The corresponding data should read as ‘Palacos R + 30 mg AmBisome®, Palacos R + G + 30 mg AmBisome®, Palacos R + G + 100 mg AmBisome® and Copal G + C + 50 mg AmBisome®’. Both the incorrect and the corrected Table 2 are displayed below.

Incorrect Table 2

Table 2 Methodology of in-vitro testing

Cement formulation	Test/Limit				
	Compressive Strength [MPa]	Bending Modulus [MPa]	Bending Strength [MPa]	Impact/Strength [kJ/m ²]	Elution in µg per sample
	< 70 Mpa	< 1800 Mpa	< 50 Mpa	< 2.5kJ/m2	
Palacos R plain	☑	☑	☑	☑	
Palacos R + 0.5 g pure Amphotericin B					☑
Palacos R + 0.8 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + 30 g AmBisome®	☑	☑	☑	☑	
Palacos R + G plain	☑	☑	☑	☑	
Palacos R + G + 0.8 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + G + 30 g AmBisome®	☑	☑	☑	☑	
Palacos R + G + 2.66 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + G + 100 g AmBisome®	☑	☑	☑	☑	
Copal G + C plain	☑	☑	☑	☑	
Copal G + C + 50 g AmBisome®	☑	☑	☑	☑	

Correct Table 2

Table 2 Methodology of in-vitro testing

Cement formulation	Test/Limit				
	Compressive Strength [MPa]	Bending Modulus [MPa]	Bending Strength [MPa]	Impact/Strength [kJ/m ²]	Elution in µg per sample
	< 70 Mpa	< 1800 Mpa	< 50 Mpa	< 2.5kJ/m2	
Palacos R plain	☑	☑	☑	☑	
Palacos R + 0.5 g pure Amphotericin B					☑
Palacos R + 0.8 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + 30 mg active ingredient/0,8 g AmBisome®	☑	☑	☑	☑	
Palacos R + G plain	☑	☑	☑	☑	
Palacos R + G + 0.8 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + G + 30 mg active ingredient/0,8 g AmBisome®	☑	☑	☑	☑	
Palacos R + G + 2.66 g pure Amphotericin B	☑	☑	☑	☑	
Palacos R + G + 100 mg active ingredient 2,66 g AmBisome®	☑	☑	☑	☑	
Copal G + C plain	☑	☑	☑	☑	
Copal G + C + 50 mg active ingredient/1,33 g AmBisome®	☑	☑	☑	☑	

The original article has been corrected.

Published online: 29 March 2025

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.